 Metformin
"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 0 | 2 | | 2004 | 2 | 0 | 2 | | 2005 | 3 | 4 | 7 | | 2006 | 1 | 2 | 3 | | 2007 | 6 | 5 | 11 | | 2008 | 3 | 4 | 7 | | 2009 | 7 | 2 | 9 | | 2010 | 1 | 3 | 4 | | 2011 | 3 | 1 | 4 | | 2012 | 7 | 4 | 11 | | 2013 | 4 | 2 | 6 | | 2014 | 8 | 6 | 14 | | 2015 | 8 | 3 | 11 | | 2016 | 2 | 3 | 5 | | 2017 | 9 | 5 | 14 | | 2018 | 10 | 3 | 13 | | 2019 | 5 | 6 | 11 | | 2020 | 9 | 1 | 10 | | 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Tesfaldet B, Tryggestad J, White NH, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021 07 29; 385(5):416-426.
-
Brooks-Worrell BM, Tjaden AH, Edelstein SL, Palomino B, Utzschneider KM, Arslanian S, Mather KJ, Buchanan TA, Nadeau KJ, Atkinson K, Barengolts E, Kahn SE, Palmer JP. Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study. Front Immunol. 2021; 12:640251.
-
Tommerdahl KL, Bjornstad P, Kendrick J, Cree-Green M, Baumgartner AD, Pyle L, Reusch JEB, Nadeau KJ. Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes. Diabetes Obes Metab. 2021 03; 23(3):844-849.
-
Aroda VR, Christophi CA, Edelstein SL, Perreault L, Kim C, Golden SH, Horton E, Mather KJ. Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program. BMJ Open Diabetes Res Care. 2020 12; 8(2).
-
Misitzis A, Stratigos AJ, Beatson M, Mastorakos G, Dellavalle RP, Weinstock MA. The association of metformin use with keratinocyte carcinoma development in high-risk patients. Dermatol Ther. 2020 11; 33(6):e14402.
-
Ryder JR, Xu P, Nadeau KJ, Kelsey MM, Xie C, Jenkins T, Inge TH, Bjornstad P. Effect of surgical versus medical therapy on estimated cardiovascular event risk among adolescents with type 2 diabetes and severe obesity. Surg Obes Relat Dis. 2021 Jan; 17(1):23-33.
-
Rasouli N. An Escape From Diabetes. J Clin Endocrinol Metab. 2020 09 01; 105(9).
-
Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020 11 17; 173(10):813-821.
-
Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 09; 43(9):e108-e110.
-
Panaro BL, Yusta B, Matthews D, Koehler JA, Song Y, Sandoval DA, Drucker DJ. Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. Mol Metab. 2020 07; 37:100990.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|